Žirmūnų psichikos sveikatos centras

Study Suggests ADHD Drugs Could Treat Alzheimer’s Symptoms

Žirmūnų psichikos sveikatos centro naujienos

Key Takeaways

  • Researchers suggested that ADHD medications may alleviate some symptoms of Alzheimer’s disease.
  • The drugs specifically helped improve cognition and apathy in Alzheimer's patients.
  • Repurposing drugs could speed up the approval process and reduce the costs of having to develop an entirely new medication.


Treatment options for Alzheimer’s disease are limited, but new research suggests that medications for attention deficit hyperactivity disorder (ADHD) may treat certain symptoms of Alzheimer’s.


An analysis published in the Journal of Neurology Neurosurgery & Psychiatry reviewed 19 clinical trials on the use of noradrenergic drugs—often used to treat anxiety, depression, and ADHD—in people with neurodegenerative disease.


Researchers found that these drugs can improve general cognitive performance and apathy, the most common neuropsychiatric symptom in Alzheimer’s patients.


Related: Study: Flu Shots May Reduce the Risk of Alzheimer's Disease


Michael C. B. David, the lead author of the study and a clinical research fellow at Imperial College London, said that current Alzheimer’s treatment only has “modest effects on symptoms.”


Since existing research suggested that changes in Alzheimer’s patients first occur in the brain’s noradrenergic system, which regulates alertness and arousal, David and his team wanted to look into the effectiveness of the drugs that are designed for this system.


The noradrenergic system affects the attention span in people with ADHD, David explained. “Patients with Alzheimer’s disease also struggle with attention, so we predicted this might be improved with these drugs,” he said.


Related: Dementia Cases Expected to Triple by 2050


Limited Treatment Options for Alzheimer’s Disease

Currently, treatments exist to delay or manage certain symptoms of Alzheimer’s, but there is no cure.


Cholinesterase inhibitors, including Aricept (donepezil), Exelon (rivastigmine), and Razadyne (galantamine), are approved to treat Alzheimer’s symptoms. These drugs may help stabilize or improve brain functions and delay the progression of symptoms for some patients.


Aduhelm (aducanumab) is the only FDA-approved drug that targets the underlying cause of Alzheimer’s rather than its symptoms only. But Aduhelm is controversial: Some experts have argued that the clinical data didn’t actually show the drug helped slow cognitive decline, and the medication comes with the risk of serious side effects, such as brain swelling or bleeding.


Related: Why Is the FDA Approval of a New Alzheimer's Drug So Controversial?


Megan Maroney, PharmD, a clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers University, told Verywell that in the early stage of Alzheimer’s, some of the cognitive functioning is “quite similar to what we see in an individual with ADHD, including difficulty with attention and short-term memory.”


Maroney added that the noradrenergic drugs reviewed in the study are “sometimes used off-label for depression in elderly patients,” so it makes sense that they might be useful for Alzheimer’s patients as well.


The current standard of care for Alzheimer’s is to “prevent further decline in cognition, not necessarily to improve it,” according to Maroney. “If we can find a medication that safely and effectively improves functioning, that would be a big step,” she said.


Related: Study Finds Treating Depression in Dementia Patients Goes Beyond Drugs


The Potential Benefits of Repurposing ADHD Drugs for Alzheimer’s Disease

Amit Sachdev, MD, director of the division of neuromuscular medicine at Michigan State University, said that “the most important consideration is how a drug works rather than what it is approved for” as treatment options for Alzheimer’s are limited.


“Many medications are initially improved for an easily measurable and relatively well-understood disease. As the brain is better understood, existing medications are often repurposed,” Sachdev said.

If ADHD drugs were to be approved for use in Alzheimer’s patients, the process would be much faster than designing a new drug, Maroney noted.


“Studying a brand-new medication can take years and years of development and study, which also carries a significant cost burden,” she said. “If we can repurpose a medication that is already on the market, we can start using it in patients much more quickly. It would simply be a matter of studying it for safety and efficacy in this target population. We’d already have a massive head start.”


Related: Getting Too Little Sleep in Middle Age May up Your Dementia Risk


What This Means For You

A new study showed that ADHD drugs might improve cognitive abilities and apathy in Alzheimer’s patients. However, more research is needed to see if they could be added to the arsenal of drugs to treat Alzheimer’s disease.



https://www.verywellhealth.com/adhd-drugs-for-alzheimers-disease-5705808

Google Translate
Mediacijos paslaugos
SKIRTINGOS SPALVOS 10 LAIDA - Justės Arlauskaitės-Jazzu istorija (savižudybių prevencija)
16 birž., 2023
Socialinė iniciatyva Skirtingos Spalvos pristato dešimtąją laidą ir jos pašnekovę – Justę Arlauskaitę-Jazzu. Šioje laidoje žinoma atlikėja kalbėjo apie emocinę sveikatą ir savižudybių prevenciją Itin atvirame pokalbyje Justė pasidalijo įvairiomis gyvenimo patirtimis apie santykius su žmonėmis, vaikystėje išmoktas pamokas, ilgai trukusią kovą su priklausomybėmis, panikos atakomis, kelionę sveikimo link ir iš naujo užgimusią Justę, kuomet ant rankų pradėjo sūpuoti savo sūnų Majų. Kaip ir pati Justė laidos metu atviravo, kad gyvenime atlikėja save suprato kaip balsą, o kai jį staiga prarado, nebematė tikslo toliau gyventi, jautėsi nereikalinga nei sau, nei kitiems. Užtruko laiko save susirinkti ir suprasti, kad Justė nėra tik apie balsą. „Pradėjau remtis į kitus žmones, ieškoti pagalbos, kurios nėra gėda ieškoti, tai yra drąsa prašyti pagalbos ir eiti šviesos link“, – atvirauja Justė.
EPA 2023
05 bal., 2023
Kovo 25-28 dienomis Paryžiuje vyko 31- asis Europos psichiatrų kongresas, kuriame dalyvavo du gydytojai psichiatrai iš mūsų centro. Daug naujų tyrimų, gydymo metodų. Kiekvieną dieną buvo skaitoma po 2 pranešimus apie ADHD. Europoje šiam sutrikimui pastaruoju metu skiriamas didelis dėmesys.
27 vas., 2023
Scientists have made a startling discovery. According to a new study researchers presented at the 35th Annual European College of Neuropsychopharmacology in Vienna, certain anti-depressants can cause drastic changes in the brain. In fact, they may even be able to rewire brains affected by major depressive disorder. Major depressive disorder, or MDD as I’ll refer to it from here out, is a mental health disorder that is characterized by persistent depressing moods, dark thoughts, and a general loss of interest in any activities. It can cause major impairment in the daily lives of people affected by it. Now, though, we may be able to treat it by using certain anti-depressants to change how the brain is wired. In the past, researchers have found that anti-depressants and even behavioral therapy and electroconvulsive therapy just don’t work for everyone that suffers from MDD. However, a group of researchers in Germany are now claiming that anti-depressants can change the brain structures themselves. However, they aren’t sure how long those changes will remain. Past studies have found that serious bouts of depression are often associated with a change in the volume of gray matter and white matter found within the brain. Each type of brain matter is associated with different functions of the body, and any changes in them can drastically change how our brains react. As such, being able to change the brain’s structure with anti-depressants is huge.
Share by: